Oral pemphigus vulgaris associated with HIV infection.
Vesiculobullous disease in association with HIV infection is extremely rare. This report details the presentation and management of pemphigus vulgaris in an individual with HIV infection. The clinical characteristics and response to therapy appear not to be modified by coexistent HIV infection. However, the management of pemphigus vulgaris relies on immunosuppressive therapy potentially resulting in HIV disease progression. Cyclosporine has in vitro antiretroviral activity and, currently, should be considered as a possible treatment for individuals with pemphigus vulgaris and HIV infection.
Hodgson
Tim A
TA
Unit of Oral Medicine, Eastman Dental Institute for Oral Health Care Sciences, University College, London, UK. T.Hodgson@eastman.ucl.ac.uk
Fidler
Sarah J
SJ
Speight
Paul M
PM
Weber
Jonathan N
JN
Porter
Stephen R
SR
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D016572:Cyclosporine / Q000627:therapeutic use*; D018450:Disease Progression; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D010392:Pemphigus / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology
D007166:Immunosuppressive Agents; D016572:Cyclosporine